1 min read
Add as a preferred source on Google

Aytu Revenue Rises to $14.842 Million as Tender Offer Remains Pending

Revenue was $13.888 million in the year-earlier quarter. Aytu also had $25.5 million in cash and cash equivalents.

A medicine blister pack rests beside a sealed envelope / TokenPost.ai (mono)
A medicine blister pack rests beside a sealed envelope / TokenPost.ai (mono)

Aytu BioPharma, Inc. posted $14.842 million in net revenue for the quarter ended Sept. 30, 2026, up from $13.888 million a year earlier, as Rosemont’s $2.70 cash offer remained pending.

The agreement announced Nov. 16 calls for Rosemont Pharmaceuticals’ wholly owned subsidiary to offer $2.70 in cash for each outstanding Aytu common share. The tender offer had not commenced as of Nov. 16 and is subject to conditions, including tenders covering a majority of Aytu’s outstanding shares. The agreement has no financing condition.

Aytu had $25.5 million in cash and cash equivalents. The company will not hold an earnings call because of the pending merger.

“We see a strong strategic fit between our portfolio and Rosemont’s experience developing and commercializing specialty medicines,” Aytu CEO Josh Disbrow said.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…